An inflammatory mediator, prostaglandin e2, in colorectal cancer

Cancer Journal (United States)

Volumn 19, Issue 6, 2013, Pages 502-510

  Wang, Dingzhi ^a   Dubois, Raymond N ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Colorectal cancer; Cyclooxygenase Derived Prostaglandin E 2 (Pge2); Risk Factors; Tumor Induced Immunosuppression

Indexed keywords

ARACHIDONIC ACID; ARGINASE 1; B LYMPHOCYTE RECEPTOR; B7 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 4; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; RETINAL DEHYDROGENASE; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; B LYMPHOCYTE; CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; COLORECTAL CANCER; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; FAT INTAKE; FATTY ACID METABOLISM; HELPER CELL; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MAST CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; COLORECTAL NEOPLASMS; DINOPROSTONE; HUMANS; RISK FACTORS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84889023629     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000003     Document Type: Review

References (136)

1. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal antiinflammatory drugs. Adv Pharmacol. 1997;39:1-20.
2. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-1952.
3. Burn J, Bishop DT, Chapman PD, et al. A randomized placebocontrolled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4:655-665.
4. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081-2087.
5. Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134:29-38.
6. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
7. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328-336.
8. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.
9. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518-527.
10. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591-1601.
11. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356: 2131-2142.
12. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649-658.
13. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183-1188.
14. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11-21.
15. Marnett LJ, DuBois RN. COX-2: A target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55-80.
16. Ogino S, Kirkner GJ, Nosho K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008;14:8221-8227.
17. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709-1711.
18. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122:518-523.
19. Wang D, Dubois RN. Cyclooxygenase-2: A potential target in breast cancer. Semin Oncol. 2004;31:64-73.
20. McLemore TL, Hubbard WC, Litterst CL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1988;48:3140-3147.
21. Hambek M, Baghi M, Wagenblast J, et al. Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck. 2007;29:244-248.
22. Cai Q, Gao YT, Chow WH, et al. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol. 2006;24:5010-5016.
23. Johnson JC, Schmidt CR, Shrubsole MJ, et al. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol. 2006;4:1358-1365.
24. Dong LM, Shu XO, Gao YT, et al. Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. Cancer Epidemiol Biomarkers Prev. 2009;18:3075-3078.
25. Kim S, Taylor JA, Milne G, et al. Association between urinary prostaglandin E2 metabolite and breast cancer risk: A prospective, case-cohort study of postmenopausal women. Cancer Prev Res (Phila). 2013;6:511-518.
26. Morris PG, Zhou XK, Milne GL, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila). 2013;6:428-436.
27. Kekatpure VD, Boyle JO, Zhou XK, et al. Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prev Res (Phila). 2009;2:957-965.
28. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280:3217-3223.
29. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-betaYinduced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A. 2004;101:17468-17473.
30. Ding Y, Tong M, Liu S, et al. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis. 2005;26:65-72.
31. Gee JR, Montoya RG, Khaled HM, et al. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol. 2003;21:266-270.
32. Murphey LJ, Williams MK, Sanchez SC, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004;334:266-275.
33. Kawamori T, Uchiya N, Sugimura T, et al. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis. 2003;24:985-990.
34. Wang D, Wang H, Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell. 2004;6:285-295.
35. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006;103:12098-12102.
36. Nakanishi M, Montrose DC, Clark P, et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008;68: 3251-3259.
37. Watanabe K, Kawamori T, Nakatsugi S, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999;59:5093-5096.
38. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002;62:28-32.
39. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med. 2001;7:1048-1051.
40. Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181-193.
41. Xia D, Wang D, Kim SH, et al. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med. 2012;18:224-226.
42. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55: 115-122.
43. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
44. Della Porta M, Danova M, Rigolin GM, et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology. 2005;68:276-284.
45. Huang A, Gilmour JW, Imami N, et al. Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration. Clin Exp Immunol. 2003;134:270-278.
46. Wu YG, Wu GZ, Wang L, et al. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo. Med Oncol. 2010;27:736-742.
47. Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004;11:328-339.
48. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 2004;64:5535-5538.
49. Chinen T, Komai K, Muto G, et al. Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nat Commun. 2011;2:190.
50. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest. 2003;111:727-735.
51. Stock A, Booth S, Cerundolo V. Prostaglandin E2 suppresses the differentiation of retinoic acidYproducing dendritic cells in mice and humans. J Exp Med. 2011;208:761-773.
52. Jung ID, Jeong YI, Lee CM, et al. COX-2 and PGE2 signaling is essential for the regulation of IDO expression by curcumin in murine bone marrowYderived dendritic cells. Int Immunopharmacol. 2010;10: 760-768.
53. von Bergwelt-Baildon MS, Popov A, Saric T, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: Additional mechanisms of T-cell inhibition. Blood. 2006;108:228-237.
54. Harizi H, Juzan M, Pitard V, et al. Cyclooxygenase-2-issued prostaglandin E(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol. 2002;168: 2255-2263.
55. Sheibanie AF, Yen JH, Khayrullina T, et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-9IL-17 axis. J Immunol. 2007;178: 8138-8147.
56. Fabricius D, Neubauer M, Mandel B, et al. Prostaglandin E2 inhibits IFN-alpha secretion and TH1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J Immunol. 2010;184:677-684.
57. Muthuswamy R, Mueller-Berghaus J, Haberkorn U, et al. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood. 2010;116: 1454-1459.
58. Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 2011;118:5498-5505.
59. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555.
60. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39-51.
61. Bacman D, Merkel S, Croner R, et al. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: A retrospective study. BMC Cancer. 2007;7:156.
62. Eruslanov E, Kaliberov S, Daurkin I, et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: A mechanism for immune evasion in cancer. J Immunol. 2009;182:7548-7557.
63. Oshima H, Hioki K, Popivanova BK, et al. Prostaglandin E signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology. 2010;140:596e7-607e7.
64. Kunkel SL, Spengler M, May MA, et al. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem. 1988;263:5380-5384.
65. Aronoff DM, Canetti C, Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptorYmediated increase in intracellular cyclic AMP. J Immunol. 2004;173:559-565.
66. Canetti C, Serezani CH, Atrasz RG, et al. Activation of phosphatase and tensin homolog on chromosome 10 mediates the inhibition of FcgammaR phagocytosis by prostaglandin E2 in alveolar macrophages. J Immunol. 2007;179:8350-8356.
67. Hubbard LL, Ballinger MN, Thomas PE, et al. A role for IL-1 receptorYassociated kinase-M in prostaglandin E2Yinduced immunosuppression post-bone marrow transplantation. J Immunol. 2010;184: 6299-6308.
68. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer. 2005;117:574-586.
69. Shimozato T, Kincade PW. Prostaglandin E(2) and stem cell factor can deliver opposing signals to B lymphocyte precursors. Cell Immunol. 1999;198:21-29.
70. Brown DM, Warner GL, Ales-Martinez JE, et al. Prostaglandin E2 induces apoptosis in immature normal and malignant B lymphocytes. Clin Immunol Immunopathol. 1992;63:221-229.
71. Prijatelj M, Celhar T, Mlinaric-Rascan I. Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells. Prostaglandins Other Lipid Mediat. 2011;95:19-26.
72. Murn J, Alibert O, Wu N, et al. Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. J Exp Med. 2008;205:3091-3103.
73. Roper RL, Phipps RP. Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J Immunol. 1992;149:2984-2991.
74. Roper RL, Graf B, Phipps RP. Prostaglandin E2 and cAMP promote B lymphocyte class switching to IgG1. Immunol Lett. 2002;84:191-198.
75. Roper RL, Brown DM, Phipps RP. Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. J Immunol. 1995;154:162-170.
76. Espi A, Arenas J, Garcia-Granero E, et al. Relationship of curative surgery on natural killer cell activity in colorectal cancer. Dis Colon Rectum. 1996;39:429-434.
77. Kondo E, Koda K, Takiguchi N, et al. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003;20:445-451.
78. Yakar I, Melamed R, Shakhar G, et al. Prostaglandin E(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol. 2003;10:469-479.
79. Voth R, ChmielarczykW, Storch E, et al. Induction of natural killer cell activity in mice by injection of indomethacin. Nat Immun Cell Growth Regul. 1986;5:317-324.
80. Ma X, Holt D, Kundu N, et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology. 2013;2:e22647.
81. Goto T, Herberman RB, Maluish A, et al. Cyclic AMP as a mediator of prostaglandin EYinduced suppression of human natural killer cell activity. J Immunol. 1983;130:1350-1355.
82. Bankhurst AD. The modulation of human natural killer cell activity by prostaglandins. J Clin Lab Immunol. 1982;7:85-91.
83. Mailliard RB, Alber SM, Shen H, et al. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med. 2005;202:941-953.
84. Walker W, Rotondo D. Prostaglandin E2 is a potent regulator of interleukin-12Y and interleukin-18Yinduced natural killer cell interferongamma synthesis. Immunology. 2004;111:298-305.
85. Joshi PC, Zhou X, Cuchens M, et al. Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. J Immunol. 2001;166:885-891.
86. Liu H, Cunnick JE, Hendrich S. Opposing effects of prostaglandin E(2)and F(2 alpha) on rat liver-associated natural killer cell activity in vitro. Prostaglandins Leukot Essent Fatty Acids. 2000;63:153-158.
87. Martinet L, Jean C, Dietrich G, et al. PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type IYdependent signaling. Biochem Pharmacol. 2010;80:838-845.
88. Mandruzzato S, Solito S, Falisi E, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182: 6562-6568.
89. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49-59.
90. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-174.
91. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66: 1123-1131.
92. Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007;67:4507-4513.
93. Veltman JD, Lambers ME, van Nimwegen M, et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010;10:464.
94. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202:931-939.
95. Zhang Y, Liu Q, Zhang M, et al. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cellderived PGE2. J Immunol. 2009;182:3801-3808.
96. Obermajer N, Muthuswamy R, Odunsi K, et al. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011;71:7463-7470.
97. O'Hara RJ, Greenman J, MacDonald AW, et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res. 1998;4:1943-1948.
98. Shibata M, Nezu T, Kanou H, et al. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol. 2002;34:416-420.
99. Pellegrini P, Berghella AM, Del Beato T, et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother. 1996;42:1-8.
100. Snijdewint FG, Kalinski P, Wierenga EA, et al. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol. 1993;150:5321-5329.
101. Hilkens CM, Vermeulen H, van Neerven RJ, et al. Differential modulation of T helper type 1 (TH1) and T helper type 2 (TH2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur J Immunol. 1995;25:59-63.
102. Qian X, Gu L, Ning H, et al. Increased TH17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J Immunol. 2013;190:5894-5902.
103. Chizzolini C, Chicheportiche R, Alvarez M, et al. Prostaglandin E2 synergistically with interleukin-23 favors human TH17 expansion. Blood. 2008;112:3696-3703.
104. Boniface K, Bak-Jensen KS, Li Y, et al. Prostaglandin E2 regulates TH17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009;206:535-548.
105. Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A, et al. Prostaglandin E2 enhances TH17 responses via modulation of IL-17 and IFNgamma production by memory CD4+ T cells. Eur J Immunol. 2009;39:1301-1312.
106. Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2YEP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat Med. 2009;15:633-640.
107. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494.
108. Hendricks A, Leibold W, Kaever V, et al. Prostaglandin E2 is variably induced by bacterial superantigens in bovine mononuclear cells and has a regulatory role for the T cell proliferative response. Immunobiology. 2000;201:493-505.
109. Zeddou M, Greimers R, de Valensart N, et al. Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway. Biochem Pharmacol. 2005;70:714-724.
110. Ganapathy V, Gurlo T, Jarstadmarken HO, et al. Regulation of TCRinduced IFN-gamma release from islet-reactive non-obese diabetic CD8(+) T cells by prostaglandin E(2) receptor signaling. Int Immunol. 2000;12:851-860.
111. Ahmadi M, Emery DC, Morgan DJ. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 2008; 68:7520-7529.
112. Strauss L, Bergmann C, Gooding W, et al. The frequency and suppressor function of CD4+CD25highFOXP3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6301-6311.
113. Wolf AM,Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606-612.
114. Yaqub S, Henjum K, Mahic M, et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother. 2008;57:813-821.
115. Gounaris E, Blatner NR, Dennis K, et al. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res. 2009;69:5490-5497.
116. Nakanishi M, Menoret A, Tanaka T, et al. Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res (Phila). 2011;4:1198-1208.
117. Sharma S, Yang SC, Zhu L, et al. Tumor cyclooxygenase-2/prostaglandin E2Ydependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005;65:5211-5220.
118. Baratelli F, Lin Y, Zhu L, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol. 2005;175:1483-1490.
119. Muthuswamy R, Urban J, Lee JJ, et al. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 2008;68:5972-5978.
120. Mahic M, Yaqub S, Johansson CC, et al. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2Ydependent mechanism. J Immunol. 2006;177:246-254.
121. Soontrapa K, Honda T, Sakata D, et al. Prostaglandin E2Yprostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc Natl Acad Sci U S A. 2011;108: 6668-6673.
122. Karavitis J, Hix LM, Shi YH, et al. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PloS One. 2012;7:e46342.
123. Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol. 2009;24:1265-1275.
124. Kashiwase Y, Inamura H, Morioka J, et al. Quantitative analysis of mast cells in benign and malignant colonic lesions: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Allergol Immunopathol (Madr). 2008;36:271-276.
125. Groot Kormelink T, Abudukelimu A, Redegeld FA. Mast cells as target in cancer therapy. Curr Pharm Des. 2009;15:1868-1878.
126. Gounaris E, Erdman SE, Restaino C, et al. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A. 2007;104:19977-19982.
127. Weller CL, Collington SJ, Hartnell A, et al. Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor. Proc Natl Acad Sci U S A. 2007;104:11712-11717.
128. Kuehn HS, Jung MY, Beaven MA, et al. Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem. 2011;286:391-402.
129. Hu ZQ, Asano K, Seki H, et al. An essential role of prostaglandin E on mouse mast cell induction. J Immunol. 1995;155:2134-2142.
130. Saito H, Ebisawa M, Tachimoto H, et al. Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol. 1996;157:343-350.
131. Gomi K, Zhu FG, Marshall JS. Prostaglandin E2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP1/EP3-dependent mechanism. J Immunol. 2000;165:6545-6552.
132. Abdel-Majid RM, Marshall JS. Prostaglandin E2 induces degranulationindependent production of vascular endothelial growth factor by human mast cells. J Immunol. 2004;172:1227-1236.
133. Nakayama T, Mutsuga N, Yao L, et al. Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. J Leukoc Biol. 2006;79:95-104.
134. DeLong P, Tanaka T, Kruklitis R, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 2003;63:7845-7852.
135. Hahn T, Alvarez I, Kobie JJ, et al. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer. 2006;118: 2220-2231.
136. Zeytin HE, Patel AC, Rogers CJ, et al. Combination of a poxvirusbased vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res. 2004;64:3668-3678.